We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu
Trial record 12 of 119 for:    "ACDC"

Role of Adiponectin and Endothelial Progenitor Cells in Reperfusion Injury in Patients With Acute Myocardial Infarction (R²ACE)

This study has been completed.
ClinicalTrials.gov Identifier:
First Posted: August 11, 2011
Last Update Posted: July 21, 2015
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
M Claeys, Universiteit Antwerpen
There is experimental evidence that low levels of adiponectin are associated with more reperfusion injury. In addition experimental studies have demonstrated that endothelial progenitor cells may have a favorable effect on remodeling, mainly through stimulation of neo-revascularisation. Clinical data on these issues are lacking. This clinical project studies the role of adiponectin, endothelial progenitor cells and endothelial microparticles in the ischaemia-reperfusion process and the compensatory ventricular remodelling in a population of 250 infarction patients treated with primary PCI. If the role of these factors could be confirmed in this clinical setting, those factors might represent a new target for therapeutic interventions in AMI patients.

Myocardial Infarction Reperfusion Injury

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Reperfusion Injury and Cardiac Remodelling After Myocardial Infarction in Relation to Adiponectin Level, Circulating Endothelial Progenitor Cells and Endothelial Microparticles

Resource links provided by NLM:

Further study details as provided by M Claeys, Universiteit Antwerpen:

Primary Outcome Measures:
  • occurrence of reperfusion injury after succesfull primary PCI [ Time Frame: within 90 min after PCI ]
    Serial ECG measurements (before and after PCI to assess extent of ST segment resolution as marker of reperfusion injury

Secondary Outcome Measures:
  • Major cardiovascular event rate [ Time Frame: at 1 year ]
    combined endpoint of hospitalisation (or extension of hospitalisation) for heart failure and cardiac death in a period of one year

Biospecimen Retention:   Samples Without DNA
blood samples

Enrollment: 250
Study Start Date: April 2011
Study Completion Date: December 2013
Primary Completion Date: December 2012 (Final data collection date for primary outcome measure)
STEMI patients
Patients with ST elevation myocardial infarction,lasting <12 hour, who were succesfully treated with primary PCI


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
ST elevetion myocardial infarction patients

Inclusion Criteria:

  • STEMI treated with primary PCI

Exclusion Criteria:

  • ischemia time >12h
  • use of immunosuppressive therapy
  • unsuccessful recanalisation
  • not-interpretable ST-T segment
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01414452

University hospital
Edegem, Antwerp, Belgium, 2650
Sponsors and Collaborators
Universiteit Antwerpen
Principal Investigator: Marc Claeys, MD PHD University Hospital, Antwerp
  More Information

Responsible Party: M Claeys, Prof dr, Universiteit Antwerpen
ClinicalTrials.gov Identifier: NCT01414452     History of Changes
Other Study ID Numbers: UAntwerpen
First Submitted: August 10, 2011
First Posted: August 11, 2011
Last Update Posted: July 21, 2015
Last Verified: July 2015

Keywords provided by M Claeys, Universiteit Antwerpen:
Myocardial Infarction
Reperfusion injury
endothelial progenitor cells

Additional relevant MeSH terms:
Wounds and Injuries
Myocardial Infarction
Reperfusion Injury
Pathologic Processes
Myocardial Ischemia
Heart Diseases
Cardiovascular Diseases
Vascular Diseases
Postoperative Complications